In vivo degradation of a poly(propylene fumarate)/?-tricalcium phosphate injectable composite scaffold

✍ Scribed by Peter, Susan J. ;Miller, Seth T. ;Zhu, Guoming ;Yasko, Alan W. ;Mikos, Antonios G.

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 267 KB
• Volume: 41
• Category: Article
• ISSN: 0021-9304
• DOI: 10.1002/(sici)1097-4636(199807)41:1<1::aid-jbm1>3.0.co;2-n

✦ Synopsis

This study was designed to investigate the in vivo biodegration and biocompatibility of a poly(propylene fumarate) (PPF)-based orthopedic biomaterial. The effects of varying the PPF to N-vinyl pyrrolidinone ratio and PPF to ␤-tricalcium phosphate content were studied. The composite mechanical properties and local tissue interactions were analyzed over 12 weeks. An initial increase in both compressive modulus and strength was seen for composite formulations that incorporated ␤-tricalcium phosphate. The samples incorporating a higher PPF to N-vinyl pyrrolidinone ratio reached a maximal compressive strength of 7.7 MPa and a maximal compressive modulus of 191.4 MPa at 3 weeks. The lower PPF to N-vinyl pyrrolidinone ratio samples gained a maximum compressive strength of 7.5 MPa initially and a compressive modulus of 134.0 MPa at 1 week. At 6 weeks, all samples for formulations incorporating ␤-tricalcium phosphate crumbled upon removal and were not mechanically tested. Samples that did not incorporate ␤-tricalcium phosphate were very weak and insufficient for bone replacement at the 4-day time point and beyond. Tissue interactions resulted in a mild inflammatory response at the initial time points and mature fibrous encapsulation by 12 weeks.